Mesalamine
Treatment for Ulcerative Colitis
Typical Dosage: Oral: 1.2-4.8 g/day; Rectal: 1g daily
Effectiveness
75%
Safety Score
75%
Clinical Trials
144
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
Oral: 1.2-4.8 g/day; Rectal: 1g daily
Time to Effect
2-4 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,800
Monitoring:$350
Side Effect Mgmt:$125
Total Annual:$2,275
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$3,791.67
Cost per Remission
$5,687.5
Mesalamine Outcomes
for Ulcerative Colitis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
Headache
+18%
Nausea
+12%
Diarrhea
+7%
Abdominal pain
+7%
Rash
+2%
Active Clinical Trials
4 active trials recruiting for Mesalamine in Ulcerative Colitis
Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine
NCT06525974NOT YET RECRUITINGEARLY_PHASE1
46 participants
INTERVENTIONAL
Started: Sep 1, 2024
Desloratadine in Patients With Ulcerative Colitis
NCT07333716NOT YET RECRUITINGPHASE2
44 participants
INTERVENTIONAL
Shibīn al Kawm, Egypt
Started: Feb 1, 2026
Rupatadine in Patients With Ulcerative Colitis
NCT07064707RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Alexandria, Egypt
Started: Jul 15, 2025
Nitazoxanide in Patients With Ulcerative Colitis
NCT06993974RECRUITINGPHASE2
70 participants
INTERVENTIONAL
Alexandria, Egypt
Started: May 30, 2025
Completed Clinical Trials
12 completed trials for Mesalamine in Ulcerative Colitis
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)
NCT00577473COMPLETEDPHASE3
301 participants
INTERVENTIONAL
Birmingham, United States +43 more
Started: Feb 1, 2001
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
NCT01130844COMPLETEDPHASE1
52 participants
INTERVENTIONAL
Little Rock, United States +18 more
Started: Oct 8, 2010
ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA
NCT05992142COMPLETEDPHASE4
200 participants
INTERVENTIONAL
Bonheiden, Belgium +15 more
Started: Jan 17, 2023
Canadian Active & Maintenance Modified Pentasa Study
NCT00603733COMPLETEDPHASE3
288 participants
INTERVENTIONAL
Calgary, Canada +26 more
Started: Oct 1, 2007
A Double Blind Study for the Treatment of Acute Ulcerative Colitis
NCT00350415COMPLETEDPHASE3
772 participants
INTERVENTIONAL
Alabaster, United States +134 more
Started: Jun 1, 2006
Dose Escalation and Remission (DEAR)
NCT00652145COMPLETEDPHASE4
119 participants
INTERVENTIONAL
Naples, United States +7 more
Started: Sep 1, 2008
Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission
NCT00209300COMPLETEDPHASE3
362 participants
INTERVENTIONAL
Brussels, Belgium +68 more
Started: May 1, 2005
Asacol Dosing Study for Active Ulcerative Colitis
NCT00194818COMPLETEDPHASE4
7 participants
INTERVENTIONAL
Seattle, United States
Started: Jun 1, 2003
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
NCT02522780COMPLETEDPHASE3
276 participants
INTERVENTIONAL
Little Rock, United States +95 more
Started: Feb 1, 2016
Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis
NCT00343850COMPLETEDPHASE3
30 participants
INTERVENTIONAL
Chicago, United States
Started: Sep 1, 2006
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
NCT02522767COMPLETEDPHASE3
228 participants
INTERVENTIONAL
Little Rock, United States +92 more
Started: Oct 1, 2015
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
NCT00151892COMPLETEDPHASE3
829 participants
INTERVENTIONAL
Birmingham, United States +141 more
Started: Apr 8, 2005
Showing 20 of 147 total trials